Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

2008651 citationsJournal Articlebronze Open Access

Authors

Michael C. Heinrich · Dana-Farber Brigham Cancer Center

Kouros Owzar · Dana-Farber Brigham Cancer Center

Christopher L. Corless · Dana-Farber Brigham Cancer Center

Donna Hollis · Dana-Farber Brigham Cancer Center

Ernest C. Borden · Dana-Farber Brigham Cancer Center

Christopher D.�M. Fletcher · Dana-Farber Brigham Cancer Center

Christopher W. Ryan

Abstract

We confirmed the favorable impact of KIT exon 11 genotype when compared with KIT exon 9 and wild-type genotype for patients with advanced GIST who are treated with imatinib.

Topics & Keywords

Gastrointestinal Tumor Research and Treatment Gastrointestinal disorders and treatments Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 26, Issue 33, pp. 5360-5367

DOI: 10.1200/jco.2008.17.4284

Field-Weighted Citation Impact: 26.78